Drugs / JNJ-26866138
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00985959 | Jul 2008 → Jun 2010 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-26866138 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00985959 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT00985959 ↗ |